HCPCS Level II code J9229 denotes inotuzumab ozogamicin, an antibody–drug conjugate administered intravenously and billed per 0.1 mg. The code matters nationally because it supports consistent billing for a high-cost oncology injectable used in specific hematologic malignancies; accurate coding affects reimbursement, prior authorization workflows, and cost reporting across payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for inotuzumab ozogamicin, how the HCPCS Level II code maps to dosage-based billing, and typical sites of service where doses are administered. The publication presents national benchmarks for coverage and payment variability across major payers, summarizes applicable policy considerations and prior authorization trends, and outlines common billing elements and modifiers used alongside J9229.

This summary equips billing managers, revenue cycle staff, and policy analysts with the information needed to align coding practices with payer requirements, manage high-cost drug workflows, and anticipate administrative steps tied to infusion services for oncology patients.